Spectral Medical's PMX enters FDA substantive review for septic shock
Spectral Medical has moved into the substantive review phase of its US Food and Drug Administration Premarket Approval process for PMX, its endotoxin-removal haemoperfusion device, after the agency formally accepted the company's PMA application in late June. The Toronto-listed company (TSX: EDT) submitted the application on 28 May 2026, with the filing acceptance confirmed on 25 June, triggering the final US$1 million tranche of a US$2 million advance from distribution partner Vantive.
The regulatory milestone is the central event of an otherwise operationally quiet quarter. Spectral's Q2 2026 revenue came in at CAD$621,000, down 24% year-on-year, as reagent sales and service revenue contracted following the conclusion of a Vantive PrisMax sub-study in May. The six-month figure of CAD$1.51 million was slightly ahead of the prior-year comparable, supported by EAA instrumentation sales.
Tigris trial: 12-month follow-up
The PMA submission incorporated final 12-month follow-up data from the Tigris confirmatory trial. Spectral reported 100% patient follow-up, with mortality at 12 months of 52.8% in the PMX-treated cohort against 66.7% in the standard-of-care arm. That represents an absolute mortality reduction of 13.9% and a number needed to treat of 7.2. Initial Bayesian analyses, based solely on the randomised Tigris data, indicated a 95.9% probability of benefit at 12 months.
Chief Medical Officer John A. Kellum said: "The consistency of benefit across multiple clinically meaningful endpoints further strengthens the totality of evidence supporting PMX as a targeted therapy for patients with endotoxic septic shock."
The persistence of the survival advantage from 28 days through to one year is the key data point the FDA will weigh. Bayesian trial designs remain comparatively uncommon in device submissions, and the agency's willingness to file the PMA suggests it was satisfied with the statistical framework set out in the application.
Regulatory path and commercial readiness
Spectral is now preparing for pre-approval inspections at both its own facilities and those of device manufacturer Toray. Vantive, the exclusive US and Canadian distribution partner, is expected to file a 510(k) application for its PrisMax system, which the company is positioning as the primary ICU platform for PMX infusion.
The sepsis device space has few direct competitors at the PMA stage in the US market. PMX holds FDA Breakthrough Device Designation, granted in July 2022, which provides for more intensive agency interaction during review and, historically, has correlated with faster median review times. PMX is already approved in Japan and Europe and has accumulated more than 360,000 units sold globally, a commercial track record that may support the safety profile presented to the FDA.
Financially, the picture is tighter. Cash stood at CAD$803,000 at 30 June 2026, down from CAD$4.07 million at year-end 2025, and total liabilities of CAD$73.3 million substantially exceed total assets of CAD$3.2 million. Management said it is actively evaluating financing scenarios intended to provide runway beyond any potential PMX commercialisation. With approximately 330,000 patients diagnosed with septic shock annually in North America, the commercial prize is significant, but Spectral will need to resolve its balance sheet position before or alongside any FDA approval to fund a market launch effectively.